Chelsea L Collins1, Jemily Malvar2, Ann S Hamilton3,4, Dennis M Deapen3,4, David R Freyer2,5. 1. Department of Pediatrics, Loma Linda University School of Medicine, Loma Linda, California. 2. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California. 3. Los Angeles Cancer Surveillance Program, University of Southern California Keck School of Medicine, Los Angeles, California. 4. Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California. 5. Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, California.
Abstract
BACKGROUND: Poor accrual to cancer clinical trials may contribute to the lower improvement in survival observed for adolescents and young adults (AYAs) (those aged 15-39 years) with cancer. This has been difficult to quantify without reliable mechanisms to link incident cases with study enrollments. Using unique resources available at their National Cancer Institute-designated comprehensive cancer center, the authors compared the percentage of AYAs, children, and older adults enrolled onto cancer clinical trials and determined predictors of enrollment. METHODS: Patients diagnosed with cancer from January 2008 through December 2012 at 1 pediatric and 2 adult University of Southern California hospitals were identified through the California Cancer Registry and individually linked to institutional trial enrollment databases. The availability of clinical trials was assessed. RESULTS: Across the center, the enrollment percentage for AYAs (6%) was equal to that of older adults (6%), but was less than that for children (22%) (P < .01). Within the children's hospital, the AYA enrollment percentage was also less than that for children (15% vs 23%, respectively; P<.01). On multivariate analysis, diagnosis and site of care were found to be predictive of AYA enrollment onto therapeutic and nontherapeutic studies. Hispanic and Asian/Pacific Islander individuals were more likely to enroll onto nontherapeutic studies compared with non-Hispanic whites, but no racial/ethnic difference was observed for therapeutic studies. CONCLUSIONS: In the current study, the percentages of AYAs and older adults enrolled onto therapeutic trials were low but similar. Diagnosis, site of care, and race/ethnicity appear to be predictive of enrollment. Prospective mechanisms must be instituted to capture reasons for nonenrollment of AYAs and develop corrective interventions.
BACKGROUND: Poor accrual to cancer clinical trials may contribute to the lower improvement in survival observed for adolescents and young adults (AYAs) (those aged 15-39 years) with cancer. This has been difficult to quantify without reliable mechanisms to link incident cases with study enrollments. Using unique resources available at their National Cancer Institute-designated comprehensive cancer center, the authors compared the percentage of AYAs, children, and older adults enrolled onto cancer clinical trials and determined predictors of enrollment. METHODS: Patients diagnosed with cancer from January 2008 through December 2012 at 1 pediatric and 2 adult University of Southern California hospitals were identified through the California Cancer Registry and individually linked to institutional trial enrollment databases. The availability of clinical trials was assessed. RESULTS: Across the center, the enrollment percentage for AYAs (6%) was equal to that of older adults (6%), but was less than that for children (22%) (P < .01). Within the children's hospital, the AYA enrollment percentage was also less than that for children (15% vs 23%, respectively; P<.01). On multivariate analysis, diagnosis and site of care were found to be predictive of AYA enrollment onto therapeutic and nontherapeutic studies. Hispanic and Asian/Pacific Islander individuals were more likely to enroll onto nontherapeutic studies compared with non-Hispanic whites, but no racial/ethnic difference was observed for therapeutic studies. CONCLUSIONS: In the current study, the percentages of AYAs and older adults enrolled onto therapeutic trials were low but similar. Diagnosis, site of care, and race/ethnicity appear to be predictive of enrollment. Prospective mechanisms must be instituted to capture reasons for nonenrollment of AYAs and develop corrective interventions.
Authors: Ernest T Hawk; Elizabeth B Habermann; Jean G Ford; Jennifer A Wenzel; Julie R Brahmer; Moon S Chen; Lovell A Jones; Thelma C Hurd; Lisa M Rogers; Lynne H Nguyen; Jasjit S Ahluwalia; Mona Fouad; Selwyn M Vickers Journal: Cancer Date: 2014-04-01 Impact factor: 6.860
Authors: W A Bleyer; H Tejeda; S B Murphy; L L Robison; J A Ross; B H Pollock; R K Severson; O W Brawley; M A Smith; R S Ungerleider Journal: J Adolesc Health Date: 1997-12 Impact factor: 5.012
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: L Fern; S Davies; T Eden; R Feltbower; R Grant; M Hawkins; I Lewis; E Loucaides; C Rowntree; S Stenning; J Whelan Journal: Br J Cancer Date: 2008-11-25 Impact factor: 7.640
Authors: Stacy D Sanford; Jennifer L Beaumont; Mallory A Snyder; Jennifer Reichek; John M Salsman Journal: Support Care Cancer Date: 2017-01-10 Impact factor: 3.603
Authors: Chelsea Anderson; Andrew B Smitherman; Clare Meernik; Teresa P Edwards; Allison M Deal; Nancy Cannizzaro; Christopher D Baggett; Chun Chao; Hazel B Nichols Journal: J Adolesc Young Adult Oncol Date: 2019-09-23 Impact factor: 2.223
Authors: Michael E Roth; Ann M O'Mara; Nita L Seibel; David S Dickens; Anne-Marie Langevin; Brad H Pollock; David R Freyer Journal: J Oncol Pract Date: 2016-03-29 Impact factor: 3.840
Authors: Margarett Shnorhavorian; David R Doody; Vivien W Chen; Ann S Hamilton; Ikuko Kato; Rosemary D Cress; Michele West; Xiao-Cheng Wu; Theresa H M Keegan; Linda C Harlan; Stephen M Schwartz Journal: Am J Clin Oncol Date: 2018-06 Impact factor: 2.339